Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a pilot phase II, prospective, non-comparative, single center trial aimed to evaluate pharmacokinetic and safety of an intermittent dosing schedule for antifungal prophylaxis in high risk patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)

NCT00083343

Candidiasis

COMPLETED PHASE2

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

NCT00095316

Candidiasis

TERMINATED PHASE3

Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)

NCT00330395

Candidiasis

COMPLETED PHASE2

Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects

NCT03340597

Invasive Aspergillosis

COMPLETED PHASE1

Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)

NCT00292071

Fungal Infection

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pharmacokinetic and safety of caspofungin, in an intermittent dosing schedule, for prophylaxis of invasive fungal (IFI) infections will be evaluated in patients receiving induction chemotherapy for treatment of acute myeloid leukemia, myelodysplastic syndrome with blast crisis or acute lymphatic leukemia.

For prophylaxis caspofungin once daily will be given three times a week after a loading phase of three days. For drug monitoring serum samples will be collected from the first day of trial medication till one day after end of therapy (EOT). Invasive fungal infections will be diagnosed analog the criteria defined by the European organization for Research and Treatment of Cancer and the Mycosis Study Group (EORTC/MSG), revised in 2008.

Caspofungin prophylaxis will be stopped after the end of neutropenia, in case of documented proven or probable invasive fungal disease and in case of a serious adverse event attributable to the study drug, for which in view of the investigator further usage of the study drug should be avoided.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fungal Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Caspofungin

Group Type EXPERIMENTAL

caspofungin

Intervention Type DRUG

Intermittent intravenous application of caspofungin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

caspofungin

Intermittent intravenous application of caspofungin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cancidas

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* acute myeloid leukemia or myelodysplastic syndrome and blast crisis or acute lymphatic leukemia
* receiving induction chemotherapy

Exclusion Criteria

* current or need of systemic antifungal therapy
* history of proven or probable invasive aspergillus infection
* pregnant or breastfeeding women
* weight more than 100 kg
* history of allergy, hypersensitivity or any serious reaction to caspofungin

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No